Oral Session

[O16] Oral Session 16　Clinical Trial Facilitation Program

Sat. Feb 19, 2022 10:10 AM - 11:40 AM Room 9 (Swan, 1F, Kyoto International Conference Center)

Chair：Natsuko Okita（Clinical Research Support Office, National Cancer Center Hospital），Hideaki Bando（Department of Gastrointestinal Oncology, National Cancer Center Hospital East）
Discussant：Koji Takeda（Office, West Japan Oncology Group）

+Add all to schedule

[O16-1] Implementation of clinical trial prescreening tests using telemedicine

^○Kumiko Umemoto¹, Yu Sunakawa¹, Sayuri Iwami², Naho Kobayashi³, Ikiru Matsumoto⁴, Shuhei Ssaito⁴, Seigo Hara⁴ (1.Department of Clinical Oncology, St.Marianna University School of Medicine, 2.CMIC HealthCare Institute Co.,Ltd., 3.Department of Oncology Center, St.Marianna University School of Medicine, 4.MICIN Inc.)

[O16-2] A Multicenter Study on Real World Data (RWD) Collection in Cancer Care

^○Shigemi Matsumoto¹, Manabu Muto² (1.Department of Real World Data R & D, Graduate School of Medicine, Kyoto University, 2.Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University)

[O16-3] Creative methods to improve treatment rate after comprehensive genomic profiling in advanced cancer

^○Sadakatsu Ikeda, Yasuko Aoyagi, Ryo Kudo, Ryuta Kakuta, Rika Noji, Jyunko Yokobori, Mika Ohki, Yumi Kobayashi, Eriko Takamine, Eri Ishibashi, Yoshihito Kano, Satoshi Miyake (Tokyo Medical and Dental University)

[O16-4] がんゲノム中核病院におけるがんゲノムプロファイリングに対する人的資源およびコストを考える

^○Yusuke Ohkuma¹, Natsuko Okita¹, Kinosita Ichiro², Shirota Hidekazu³, Nakayama Akiko⁴, Ueno Hideki⁵, Hayashi Hideyuki⁶, Tanabe Masahiko⁷, Mamesaya Nobuaki⁸, Kokuryo Toshio⁹, Matsumoto Shigemi¹⁰, Sakai Daisuke¹¹, Kochi Mariko¹², Ito Mamoru¹³, Tuchihara Kazuya⁵, Muto Manabu¹¹ (1.Section of Liaison for Cancer Genomic Medicine Hospitals, Center for Cancer Genomic and Advanced Therapeutics, National Cancer Center, 2.Division of Clinical Cancer Genomics, Hokkaido Univeristy Hospital, 3.Department of Clinical OncologyTohoku Univeristy Hospital, 4.Exploratory Oncology Research and Clinical Trial Center, National Cancer Center Hospital East, 5.Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 6.Keio Cancer Center, Keio Univeristy Hospital, 7.Department of Breast and Endocrine Surgery, The University of Tokyo Hospital, 8.Division of Thoracic Oncology, Shizuoka Cancer Center, 9.Medical Genomics Center, Nagoya Univeristy Hospital, 10.Department of Therapeutic Oncology, Kyoto Univeristy Hospital, 11.Center for Cancer Genomics and Personalized Medicine, Osaka Univeristy Hospital, 12.Department of Clinical Genetics and Genomic Medicine, Okayama Univeristy Hospital, 13.Department of Medicine and Biosystemic Science, Kyushu Univeristy Hospital)

[O16-5] Experience and Future Challenges of Global / APAC Studies at IQVIA Japan

^○Ken Matsui, Junichiro Sawa, Naoko Higuchi, Aaka Sano, Mari Ito, Akihiro Maruhashi, Yayoi Kondo, Takanori Tsuda, Hiromi Sasamoto, Koji Ando, Jotaro Shinagawa (IQVIA Services Japan K.K.)

[O16-6] Consideration for the trends on drug lag in oncology drugs during the last two decades in Japan; 2001-2020

^○Asuka Hara¹, Momoka Ofuchi¹, Yuna Murai¹, Riko Shingai¹, Toshihiro Misumi²,Hideki Maeda¹ (1.Department of Regulatory Science, Faculty of Pharmacy, Meiji Pharmaceutical University, 2.Department of Biostatistics, Yokohama City University School of Medicine)